silevertinib monotherapy
silevertinib monotherapy: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Black Diamond Therapeutics, Inc. (BDTX)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
Frequently asked questions
Who is developing silevertinib monotherapy?
silevertinib monotherapy is being developed by Black Diamond Therapeutics, Inc..
How many clinical trials involve silevertinib monotherapy?
BioSniper tracks 1 clinical trial involving silevertinib monotherapy.
Analyze Black Diamond Therapeutics, Inc. & silevertinib monotherapy with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company